New Cervical Cancer Screening Guidelines: ACS & HRSA Updates (2026)

Cervical cancer screening recommendations have been updated by two key organizations – the American Cancer Society (ACS) and the Health Resources and Services Administration (HRSA) – with a significant shift towards prioritizing high-risk human papillomavirus (hrHPV) testing and, notably, expanding options for self-collection of samples. These changes, announced in late 2025 and January 2026 respectively, aim to increase screening rates and reduce disparities in access to care, particularly for those who may face barriers to traditional screening methods.

HPV Primary Testing: The Latest Standard

Both the ACS and HRSA now recommend that women aged 30-65 at average risk undergo primary HPV testing for cervical cancer screening. This means the initial test looks specifically for the presence of high-risk types of HPV, which are known to cause approximately 70% of cervical cancers. HPV (human papillomavirus) is a very common virus that can cause several cancers, including cervical cancer. If HPV primary testing isn’t available, both organizations suggest “co-testing,” which combines HPV testing with a Pap test (also known as cytology). If neither of those options are available, a Pap test alone remains an acceptable method.

Self-Collection: Expanding Access to Screening

Perhaps the most significant change is the endorsement of self-collected HPV tests as a viable screening option. Traditionally, samples for both HPV and Pap tests have been collected by healthcare providers during a pelvic exam. Recognizing that this can be a barrier for some individuals – due to discomfort, lack of access to care, or cultural factors – both the ACS and HRSA acknowledge the effectiveness of self-collection. Self-collection can be done in a clinical setting or, potentially, at home. It’s significant to note that this option is not recommended for individuals considered at higher risk, including those with HIV, compromised immune systems, those exposed to diethylstilbestrol (DES) in utero, or those previously treated for advanced cervical cell changes.

Navigating the Differences in Guidelines

While largely aligned, the ACS and HRSA guidelines differ slightly on the age at which screening should commence. The ACS recommends starting screening at age 25, citing the rarity of cervical cancer in younger individuals. HRSA, but, suggests initiating Pap tests at age 21, with a transition to HPV primary testing or co-testing at age 30. These differences reflect ongoing discussions within the medical community about the optimal timing for screening initiation.

Frequency of Screening and When to Stop

How often a person needs to be screened depends on the type of test used and the results. For those receiving HPV primary testing or co-testing with provider-collected samples and normal results, a repeat screening is recommended in five years. The ACS specifies that individuals who self-collect samples for HPV testing and receive normal results should be screened again in three years – a distinction not included in the HRSA guidelines. Pap tests alone require repeat screening every three years if results are normal. Abnormal results will necessitate more frequent monitoring.

Both organizations agree that screening can generally cease at age 65 if previous test results have been consistently normal. The ACS is more specific, recommending a decade of normal results – negative HPV tests at ages 60 and 65, or three consecutive negative Pap tests, with the last one at age 65. HRSA’s guidelines are less prescriptive regarding past results.

What This Means for Patients: Increased Options and Insurance Coverage

For most patients, the specific screening test offered will depend on their healthcare provider’s practice. However, the growing preference for HPV primary testing suggests a potential shift in the coming years. HRSA’s guidelines also have implications for insurance coverage. Starting January 1, 2027, most insurance plans will be required to cover all recommended testing options, including any necessary follow-up testing, without cost-sharing for the patient. This aims to remove financial barriers to accessing crucial preventative care.

Expanding Screening Locations

The acceptance of self-collected HPV tests has the potential to move cervical cancer screening beyond traditional gynecological settings. Screening could become available at primary care physician offices, urgent care clinics, mobile health units and even some pharmacies. This expanded accessibility is particularly beneficial for individuals who lack access to a gynecologist or who feel uncomfortable with pelvic exams.

Understanding the Evidence: HPV Testing and Self-Collection

The move towards HPV primary testing is supported by substantial evidence demonstrating its higher sensitivity in detecting precancerous lesions compared to traditional Pap tests. Studies have shown that HPV testing can identify individuals at higher risk of developing cervical cancer more effectively. The acceptance of self-collection is based on rigorous research confirming that the method is as effective as clinician-collected samples, offering a convenient and acceptable alternative for many women.

However, it’s crucial to remember that HPV testing is not perfect. A positive HPV test does not necessarily signify a person has or will develop cancer. Further testing and monitoring are often required to determine the appropriate course of action.

The Importance of Regular Screening

the most important message is that everyone with a cervix should undergo regular cervical cancer screening. Anyone with questions about their individual screening needs or which test is best for them should consult with a healthcare provider. Early detection through screening remains the most effective way to prevent cervical cancer.

Looking Ahead: The implementation of these updated guidelines will be an ongoing process. Healthcare providers will need to adapt their practices, and insurance companies will need to ensure coverage aligns with the new recommendations. Continued surveillance of screening rates and cervical cancer incidence will be essential to assess the impact of these changes and refine guidelines further.